SGCB and prostate cancer: We further characterized that the enhanced eNOS-NO signaling could significantly promote the growth of PCSCs regardless of their AR expression status, and also antiandrogen-resistant prostate cancer cells via the activation of downstream NO-sGC-cGMP-PKG signaling pathway, as evidenced by pharmacological inhibition of effectors in this signaling pathway.